Working… Menu

Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01521455
Recruitment Status : Completed
First Posted : January 30, 2012
Last Update Posted : August 23, 2013
Information provided by (Responsible Party):
Hanmi Pharmaceutical Company Limited

Brief Summary:
The purpose of this study is to prove that HCP0910 is therapeutically equivalent to Seretide 250 Diskus when repeatedly dosed to Asthmatic patients.

Condition or disease Intervention/treatment Phase
Asthma Drug: HCP0910 Drug: Seretide Diskus Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Randomized, Open, Multi-center, Cross Over Study to Evaluate the Therapeutic Equivalence of Repeated Dose of HCP0910 250/50 μg to SeretideTM 250 DiskusTM in Asthmatic Patients
Study Start Date : February 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: HCP0910
Fluticasone /salmeterol 250/50 combination capsule
Drug: HCP0910
250/50, BID for 2 weeks

Active Comparator: Seretide Diskus
Seretide 250 Diskus
Drug: Seretide Diskus
250/50, BID for 2 weeks

Primary Outcome Measures :
  1. mean change of morning predose FEV1 from baseline [ Time Frame: day 14 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 20 ~ 75 inclusive
  • Asthmatic diagnosis in more than 12 weeks from screening day
  • Shows more than 12 % increase, and 200mL increase in FEV1 measure on Visit 2

Exclusion Criteria:

  • Maintain controlled asthma for more than 4 weeks before screening
  • Diagnosed as a severe asthmatic patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01521455

Layout table for location information
Korea, Republic of
Soon Chun Hyang University Hospital Bucheon
Bucheon, Gyunggi -do, Korea, Republic of
Ajou University Hospital
Suwon, Gyunggi -do, Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of
Ewha Womans University Medical Center
Seoul, Korea, Republic of
Hanyang University Hospital
Seoul, Korea, Republic of
Samsung medical center
Seoul, Korea, Republic of
Seoul National University
Seoul, Korea, Republic of
Sponsors and Collaborators
Hanmi Pharmaceutical Company Limited
Layout table for investigator information
Study Director: Kyung-mi Park, Ph.D Hanmi Pharmaceutical Co.

Layout table for additonal information
Responsible Party: Hanmi Pharmaceutical Company Limited Identifier: NCT01521455     History of Changes
Other Study ID Numbers: HM-FTOL-101
First Posted: January 30, 2012    Key Record Dates
Last Update Posted: August 23, 2013
Last Verified: August 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Fluticasone-Salmeterol Drug Combination
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists